RxDoctor Payments DataLook up a doctor →

Gregory Mathews, MD

Neurology · Charleston, WVNPI 1265529374

Payments from drug & device makers

$30,235in general payments, 2019–2025

Across 499 payments — averaging $60.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurelis, Inc.$20K
  • Supernus Pharmaceuticals, Inc.$2K
  • Lilly USA, LLC$1K
  • Sunovion Pharmaceuticals Inc.$968
  • UCB, Inc.$746
  • Novo Nordisk$446
  • plus $5K from 38 others

What the payments were for

  • Speaking & faculty fees$20,96869%
  • Travel & lodging$1851%
  • Food & beverage$9,07030%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,235 in reported general payments places this provider in the 85th percentile of 93 neurology providers in West Virginia.

See all neurology providers in West Virginia

Medicare billing

Part B allowed, 2024
$138,392
Medicare patients
838
Services billed
1,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate99$227,643
BriviactBrivaracetam104$202,734
EpidiolexCannabidiol (Cbd)28$175,272
AptiomEslicarbazepine Acetate57$153,301
BanzelRufinamide12$73,080
VimpatLacosamide40$60,065
NayzilamMidazolam29$58,076
LamictalLamotrigine42$42,490
Lacosamide299$41,585
OnfiClobazam12$41,267
Keppra XrLevetiracetam17$35,854
FycompaPerampanel17$34,321
ValtocoDiazepam30$31,049
Ajovy AutoinjectorFremanezumab-Vfrm23$25,778
Lamotrigine ErLamotrigine59$21,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat, Nayzilam$746$320,875173 claims
SK Life Science, Inc.Xcopri$259$227,64399 claims
Sunovion Pharmaceuticals Inc.Aptiom$968$153,30157 claims
Eisai Inc.Banzel, Fycompa$213$107,40129 claims
Lundbeck LLCOnfi$183$41,26712 claims
Neurelis, Inc.Valtoco$20,217$31,04930 claims
AbbVieQulipta$419$17,35617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 93 neurology providers in West Virginia.

Other neurology in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →